Orabloc (Articaine Hydrochloride, Epinephrine)

Articaine hydrochloride, the active ingredient in Orabloc, is a local anesthetic (amide) presented as a solution for injection for intraoral dental use. It provides reversible loss of sensation to facilitate dental procedures in patients requiring pain control.

GNH USA supplies Orabloc as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orabloc, containing articaine, is used for local anesthesia in dental procedures.

- Dental extractions: provides profound anesthesia for tooth removal. - Restorative dentistry: enables painless cavity preparation and filling. - Periodontal surgery: facilitates anesthesia during gum and tissue manipulation.

Adverse reactions may occur following intraoral administration of articaine‑epinephrine solutions.

Common Side Effects: - Transient lip or cheek numbness. - Mild headache. - Altered taste sensation. - Mild swelling or bruising at the injection site.

Serious or Rare Side Effects: - Allergic reaction (e.g., rash, urticaria, anaphylaxis). - Prolonged numbness lasting more than 24 hours. - Cardiovascular effects such as hypertension or tachycardia due to epinephrine. - Methemoglobinemia (rare).

When using Orabloc, clinicians should observe several safety measures.

- Allergy assessment: confirm no known hypersensitivity to amide anesthetics or epinephrine. - Cardiovascular status: use cautiously in patients with uncontrolled hypertension or arrhythmias. - Pregnancy: avoid unless the expected benefit outweighs potential risk. - Age considerations: dosage adjustment may be required for pediatric patients. - Drug interactions: review concomitant medications, especially MAO inhibitors and beta‑blockers. - Store at room temperature: keep in the original container, protect from light and moisture.

Articaine‑epinephrine may interact with other agents that affect cardiovascular or nervous system function.

Major Interactions (Avoid): - Other epinephrine‑containing products: risk of excessive vasoconstriction. - Non‑selective MAO inhibitors: may potentiate hypertensive response. - Beta‑blockers: may mask tachycardia caused by epinephrine.

Moderate Interactions (Monitor Closely): - Tricyclic antidepressants: may increase cardiac effects. - Sympathomimetic drugs (e.g., phenylephrine): additive vasoconstriction. - Additional local anesthetics: cumulative toxicity risk.